Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
暂无分享,去创建一个
M. Exline | Akram Khan | W. Self | A. Ginde | S. Schrag | A. Monto | T. Rice | C. Lindsell | D. Hager | N. Shapiro | M. Gong | Yuwei Zhu | N. Mohr | K. Hart | C. Hough | N. Johnson | A. Duggal | K. Gibbs | A. Lauring | E. Martin | J. Chappell | Carlos G. Grijalva | M. Gaglani | J. Verani | N. Halasa | H. Talbot | D. Douin | J. Casey | J. Steingrub | Samantha M Olson | Steven Y. Chang | M. Tenforde | S. Ghamande | J. Rhoads | H. Babcock | M. Prekker | Jennie H. Kwon | I. Peltan | Jennifer G. Wilson | William B. Stubblefield | A. Mohamed | Samuel M Brown | A. Gordon | Nida Qadir | W. Stubblefield | H. Erickson | C. Mallow | L. Busse | D. Files | A. Zepeski | Adrienne H Baughman | Kelsey N. Womack | Vasisht Srinivasan | M. Patel | T. McNeal | A. Shehu | C. T. ten Lohuis | C. Rivas | J. P. Rhoads | K. Adams | Miwako Kobayashi | M. Kobayashi | Jennifer G. Wilson | J. Kwon | Samuel M. Brown | Christopher Mallow | A. Baughman | K. Womack | Samantha M. Olson | A. J. Gordon | N. Qadir
[1] Manish M Patel,et al. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021 , 2022, MMWR. Morbidity and mortality weekly report.
[2] J. Champati,et al. Using survey data to estimate the impact of the omicron variant on vaccine efficacy against COVID-19 infection , 2022, Scientific Reports.
[3] William F. Fadel,et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[4] Melissa G. Pike,et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 , 2022, MMWR. Morbidity and mortality weekly report.
[5] Y. Young-Xu. Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans , 2022, medRxiv.
[6] M. Lipsitch,et al. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California , 2022, medRxiv.
[7] K. Bruxvoort,et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.
[8] L. Bekker,et al. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.
[9] M. Kraemer,et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.
[10] M. Exline,et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. , 2021, JAMA.
[11] W. Schaffner,et al. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[12] David W. McDonald,et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[13] David W. McDonald,et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[14] Samuel M. Brown,et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] Joshua B. Singer,et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study , 2021, The Lancet Infectious Diseases.
[16] Samuel M. Brown,et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States , 2021, medRxiv.
[17] A. Sheikh,et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness , 2021, The Lancet.
[18] G. Kang,et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization , 2021, Vaccine.
[19] N. Jewell,et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines , 2021, medRxiv.
[20] E. Hodcroft,et al. Genetic Variants of SARS-CoV-2-What Do They Mean? , 2021, JAMA.
[21] J. Quick. nCoV-2019 sequencing protocol v3 (LoCost) , 2020 .
[22] Edward C. Holmes,et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.
[23] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[24] J. Sterne,et al. Collider bias undermines our understanding of COVID-19 disease risk and severity , 2020, Nature Communications.
[25] Eric J Tchetgen Tchetgen,et al. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. , 2016, American journal of epidemiology.